Suggested remit: To appraise the clinical and cost effectiveness of encorafenib with binimetinib within its marketing authorisation for treating BRAF V600E mutation-positive advanced non-small-cell lung cancer (NSCLC).
 
Status In progress
Technology type Medicine
Decision Selected
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
Process STA Standard
ID number 6177

Provisional Schedule

Committee meeting 13 May 2025
Expected publication 23 July 2025

Project Team

Project lead Leena Issa

Email enquiries

External Assessment Group Kleijnen Systematic Reviews Ltd

Stakeholders

Companies sponsors Pierre-Fabre (encorafenib and binimetinib)
Others Department of Health and Social Care
  NHS England
Patient carer groups Oncogene Cancer Research
  Roy Castle Lung Cancer Foundation
Professional groups Association of Cancer Physicians
  Association of Respiratory Nurse Specialists
  British Thoracic Oncology Group
  Cancer Research UK
  Royal College of Physicians
  Royal College of Radiologists
Associated public health groups None
Comparator companies Merck Sharpe & Dohme (pembrolizumab) (confidentiality agreement signed, participating)
  Novartis Pharmaceuticals (dabrafenib, trametinib) (confidentiality agreement signed, participating)
  Boehringer Ingelheim (nintedanib) (confidentiality agreement not signed, not participating)
  Bristol Myers Squibb (nivolumab) (confidentiality agreement not signed, not participating)
  Hospira UK (carboplatin, cisplatin, docetaxel, gemcitabine) (confidentiality agreement not signed, not participating)
  Medac (vinorelbine) (confidentiality agreement not signed, not participating)
  Pierre-Fabre (vinorelbine) (confidentiality agreement not signed, not participating)
  Ranbaxy [A Sun Pharmaceutical Company] (gemcitabine) (confidentiality agreement not signed, not participating)
  Roche (atezolizumab) (confidentiality agreement not signed, not participating)
  Sandoz (cisplatin) (confidentiality agreement not signed, not participating)
  Seacross Pharmaceuticals (docetaxel) (confidentiality agreement not signed, not participating)
  Synchrony Pharma (gemcitabine) (confidentiality agreement not signed, not participating)
General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Department of Health – Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare products Regulatory Agency
  Scottish Medicines Consortium
  Welsh Government
  Welsh Health Specialised Services Committee
Relevant research groups Institute of Cancer Research

Timeline

Key events during the development of the guidance:

Date Update
01 October 2024 Invitation to participate
28 June 2024 Please note that following on from a request received from the company, the timelines for this appraisal have been revised and the appraisal is now anticipated to begin in early October 2024. These timings are based on a request from the company to reschedule the initial date set by NICE, in order to facilitate a suitably comprehensive and robust submission.
24 May 2024 - 24 June 2024 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6177
24 May 2024 In progress. Scoping commencing
03 July 2023 Please note that following on from an update received from the company, appraisal has been scheduled into the work programme. The appraisal is now anticipated to begin during mid-July 2024 when we will write to you about how you can get involved. The deadline for submissions is expected in approximately mid-September 2024.
12 September 2022 Awaiting development. Status change linked to Topic Selection Decision being set to Selected

For further information on our processes and methods, please see our CHTE processes and methods manual